"The approval of HEMGENIX reflects groundbreaking science in delivering a medicine that we believe can transform the treatment options for both the people living with haemophilia B and the healthcare professionals who treat them,” said Dr Andrew Nash, senior vice president, head of research and chief scientific officer at CSL. …
Australian patients now one step closer to accessing CSL's one-time gene therapy
March 21, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News